Verrica's Phase III Success Paves Way For Filing Of New Cantharidin Formulation VP-102

 
• By Emily Hayes

After reporting positive pivotal data for VP-102 in the contagious skin disease molluscum, Verrica is looking forward to a 2020 launch, with plans to price for broad access.

Arrow flying to target with radial motion blur

More from Clinical Trials

More from R&D